Patent: 9,404,915

Summary for Patent: 9,404,915

Title:	Whole cell assays and methods
Abstract:	The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.
Inventor(s):	Laing; Lance Gavin (Belmont, MA), Sullivan; Brian Francis (Medina, MN)
Assignee:	Celcuity LLC (Minneapolis, MN)
Application Number:	14/590,731
Patent Claims:	see list of patent claims

Details for Patent 9,404,915

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-06-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-06-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-06-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-06-12
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2032-06-12
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2032-06-12